♥ HF Guideline NavigatorESC 2026

14

14 Gaps in evidence

Pages 78–80 · open in PDF

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 78 · PDF

78 Diagnosis of heart failure • Measurement of natriuretic peptides and echocardiography have key roles in the diagnosis of HF. Additional testing is useful for aetiologies and phenotypes. • Multimodality aetiology assessment should be sought to find potential treatable causes of HF. Guideline-recommended therapies

Decompensated heart failure • Decompensated heart failure refers to acute or gradual onset of symptoms and/or signs of HF, severe enough to deserve urgent medical attention, leading to an unplanned hospital admission or an emergency department visit or an ambulatory visit, and requiring subsequent initiation or intensification of treatment. • Treatment of DHF is based on addressing any associated triggers urgently, diuretics for congestion with the addition of vasodilators for high blood pressure, inotropes, and/or temporary MCS for hypoperfusion. • Patients hospitalized for HF should be carefully evaluated to exclude persistent signs of congestion. FMT must be started or optimized before discharge and close visits in the early post-discharge period must be planned. Advanced heart failure • Patients with advanced HF refractory to FMT and GDIT who do not have absolute contraindications must have timely referral for consideration of heart transplantation or MCS. Cardiovascular comorbidities • Catheter ablation should be considered only in carefully selected patients with HFrEF and symptomatic AF. Selection criteria include high-burden AF, less than 1-year duration of continuous persistent AF, and a clear cause–effect relationship between AF and HF. • Patients with obstructive CAD and HF need to be treated conservatively or invasively (CABG or PCI) according to clinical and anatomical suitability for revascularization, HF phenotype and history, presence of angina, comorbidities, frailty, and patient preference. • Surgical aortic valve replacement or TAVI, as assessed by the Heart Team, is recommended in patient with severe low-flow

low-gradient aortic stenosis and HF regardless of LVEF and in patients with severe low-flow low-gradient aortic stenosis and HFrEF. • Mitral TEER is recommended in selected patients with severe ventricular secondary MR and HFrEF after optimization of FMT and CRT implantation (if needed). Non-cardiovascular comorbidities • Patients should be routinely screened and treated for non-CV comorbidities (e.g. diabetes, CKD, obesity, ID, anxiety and depression) and frailty. • Lifestyle interventions, exercise, diet, and patient education are fundamental steps for body-weight management in patients with HF and obesity, followed by pharmacological and surgical interventions. • It is recommended to switch glucose-lowering treatment from agents without proven CV efficacy or safety to agents with proven CV benefit in patients with HF and diabetes. Multidisciplinary management • A multidisciplinary HF management programme is recommended. • Cardiac rehabilitation, with exercise training, is a key tool to reduce hospitalizations and improve functional capacity and QoL in patients with HF. • Remote haemodynamic monitoring of PA pressure should be considered in selected patients; non-invasive telemonitoring modalities may be considered. Specific conditions • Pre-conception care and counselling is recommended for patients with stage B or C HF to facilitate decision-making surrounding pregnancy. • Specific disease-modifying therapies are recommended in patients with CA.

14. Gaps in evidence Despite advances in the management of HF, multiple areas of uncertainty remain. Future research should address the following gaps. (1) Definitions and prevention • Consensus regarding normal values/ranges of ejection fraction. • More information on the incidence, prevalence and prognostic importance of HF with improved LVEF, and a need to validate and evaluate the clinical importance of the new definition proposed by the Second Universal Definition of HF.47 • The benefits and risks of various weight-loss methods for HF risk reduction in obesity need further studies. • More research is needed to understand if SGLT2-Is and MRAs prevent HF in patients without diabetes but with comorbidities like obesity, hypertension, and/or CKD. • Studies are needed to better understand if CPAP therapy lowers risk of HF in patients with sleep apnoea.

• ARNIs or ACE-Is (ARB in case of intolerance) beta-blockers, MRAs, and SGLT2-Is are recommended as FMT for patients with HFrEF, whereas MRAs and SGLT2-Is are recommended as FMT for patients with HFpEF. • ICDs are recommended in selected patients with HFrEF, LVEF ≤35%, and an ischaemic aetiology, and should be considered in those with a non-ischaemic aetiology. • CRT-P or CRT-D is recommended in patients with HFrEF, LVEF ≤35%, in sinus rhythm, with an LBBB ≥150 ms and should be considered in those with an LBBB ≥130–149 ms or non-LBBB ≥150 ms.

Page 79 · PDF

(3) Medical treatment and devices • Contemporary reproducibility of old trials on medical and device therapies. • Future trials on medical/device therapy for HF should adhere to contemporary FMT. • Randomized clinical trials comparing different MRAs in both HFrEF and HFpEF. • Randomized clinical trials investigating the optimal medical therapy for HFpEF. • Randomized clinical trials comparing different GLP-1 RAs. • Randomized clinical trials on the optimal sequencing when initiating FMT both in HFrEF and HFpEF. • More data on the role of potassium binders, both in patients with and without CKD. • Management strategies and therapies for HF with improved LVEF. • Indications for ICDs in specific subgroups of patients, and optimal selection of ICD candidates in HFrEF, including patients with ischaemic and non-ischaemic HF. • Efficacy of CRT in AF. • Randomized controlled trials with morbidity and mortality endpoints and long-term follow-up, comparing CSP and trans-coronary vein CRT in patients with HFrEF. • Randomized controlled trials with morbidity and mortality and long-term follow-up on interatrial shunt devices in patients with HFrEF and HFpEF. (4) Decompensated heart failure • Evidence on medical therapy with prognostic benefit in DHF. • Evidence for best decongestion protocols in patients with and without CKD and in the setting of continued/initiation of FMT. • Evidence-based use of imaging techniques and biomarkers that have an impact on patients’ clinical course in DHF. • Definition of evidence-based treatment options and therapeutic algorithms for patients with CS. • Better definition of the role of MCS in CS.

• Better definition of the role of inotropes, vasopressors and vasodilators in DHF. • Studies on the best early post-discharge risk-based management protocols to reduce early readmission to hospital. (5) Advanced heart failure • Benefit of FMT, AMT, and GDIT in advanced HFrEF needs further investigation. • Which medication to down-titrate/stop first in patients with advanced HF who no longer tolerate all FMT. • Durable MCS (LVADs) vs medical treatment in INTERMACS >4 without high-risk features. • Optimal lifetime management strategies in very young adults with advanced HF. • Advances in durable MCS, including strategies to reduce the risk of infection. • Advances in medical treatment for the many patients who cannot undergo MCS or heart transplantation, including development of treatment strategies, and novel inotropes or myotropes for patients with advanced HF. (6) Cardiovascular comorbidities • Adequately powered RCTs showing the best strategy for management of AF in patients with HF. • Selection of patients with HFrEF and HFpEF that may benefit from AF ablation. • Better characterization of patients with arrhythmiaassociated HF, especially patients with AF-associated HF. • Randomized controlled trials investigating best management options for patients with AF-associated HF, both in terms of HF management and management of AF. • Randomized controlled trials to assess the role of coronary revascularization and different revascularization strategies in patients with HFrEF and HFpEF on current FMT. • Longer-term follow-up results for mitral TEER interventions in HFrEF. • Role of mitral TEER in patients with HFrEF who do not fulfil specific echocardiographic and clinical criteria. • Treatment of atrial secondary MR in patients with HFpEF. • Further RCTs to assess the role of transcatheter valve intervention in patients with HF and TR. (7) Non-cardiovascular comorbidities • More clinically appropriate definition of ID in HF. • Further RCTs, using the novel definition of ID as an inclusion criterion, to assess the prognostic role of i.v. iron supplementation. • The prognostic role of HF treatment in patients with severe kidney dysfunction (i.e. eGFR <30 mL/min/ 1.73 m2), excluded from RCTs. • The effects of GLP-1 RAs and tirzepatide on morbidity and mortality in patients with HFpEF and HFrEF. • Treatment of SDB, both central and obstructive, needs further investigation to clarify benefit and safety concerns. (8) Multidisciplinary management • Studies on optimal models for follow-up of patients with stable HF.

(2) Diagnosis and phenotyping • Further research into the underlying characteristics, pathophysiology, diagnosis, and phenotyping of HFpEF. • Role of artificial intelligence in the diagnostic pathway for HF as well as for patient inclusion in RCTs. • Validated diagnostic protocols including deeper phenotyping for the diagnosis of HFpEF. • Validation of the historic exercise-induced pulmonary capillary wedge pressure cut-offs used in the diagnosis of HFpEF. • Prospective validation of age-related natriuretic peptide cut-offs in chronic HF. • Degree of influence of BMI on natriuretic peptides to allow for individual adjustment of expected ranges. • Prospective studies to test the diagnostic yield for endomyocardial biopsy, and whether a biopsy would affect treatment decisions and outcomes in patients with unexplained cardiomyopathy and evidence of inflammation/ infiltration/storage on CMR or CT-positron emission tomography.

Page 80 · PDF

15. Evidence tables Evidence tables are available at European Heart Journal online.

16. Data availability No new data were generated or analysed in support of this research.

17. Author information Author/Task Force Member Affiliations: Anne-Christine Ruwald, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; Daniela Tomasoni, Cardiology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, and Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Lisa J. Anderson, Cardiology Clinical Academic Group, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom, and Cardiovascular and Genomic Research Institute, City St George’s University of London, London, United Kingdom; Charlotte Andersson, Mass General Brigham Heart and Vascular Institute and Harvard Medical School, Boston, MA, United States of America; Jasper J. Brugts, Cardiology Department, Erasmus MC University Medical Center, Cardiovascular Institute, Rotterdam, Netherlands; Ovidiu Chioncel, Emergency Institute for Cardiovascular Diseases ‘Prof. Dr. C.C. Iliescu’, Bucharest, Romania and University of Medicine Carol Davila, Bucharest, Romania; Erwan Donal, Cardiology Department-LTSI-Inserm 1099, CHU Rennes—Université Rennes, Rennes, France; Peter Ferdinandy, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary, and Pharmahungary Group, Szeged, Hungary; Pardeep S. Jhund, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; Francisco Leyva, Aston Medical School, Aston University, Birmingham, United Kingdom, and Department of Cardiology,

University Hospitals Birmingham, Queen Elizabeth, Birmingham, United Kingdom; Roberto Lorusso, Cardio-Thoracic Surgery, Maastricht University Medical Centre (MUMC), Maastricht, Netherlands, and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands; Michael Madigan (Ireland), ESC Patient Forum, Sophia Antipolis, France; Wilfried Mullens, Cardiology Department, Ziekenhuis Oost Limburg, Genk, Belgium, and Faculty of Medicine and Life Sciences, University Hasselt, Diepenbeek, Belgium; Stefania Paolillo, Department of Advanced Biomedical Sciences, Section of Cardiology, Federico II University of Naples, Naples, Italy; Nicola Ryan, Department of Cardiology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom; Maggie Simpson, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom; Holger Thiele, Cardiology Department, Heart Center Leipzig at Leipzig University, Leipzig, Germany, and Leipzig Heart Science, Leipzig, Germany; Jens Jakob Thune, Department of Cardiology, Copenhagen University Hospital— Bispebjerg and Frederiksberg, Copenhagen, Denmark, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; Emeline M. Van Craenenbroeck, Cardiology Department, Antwerp University Hospital, Edegem, Belgium, and Cardiovascular Diseases, GENCOR, University of Antwerp, Belgium; Linda W. Van Laake, Cardiology Department, University Medical Center Utrecht, Utrecht, Netherlands, and Utrecht University, Utrecht, Netherlands, and Transplantation Center, University Medical Center Utrecht, Utrecht, Netherlands; Mariette Verbakel (Netherlands), ESC Patient Forum, Sophia Antipolis, France.

18. Appendix ESC Guidelines Advisory Group Includes Document Reviewers and ESC National Cardiac Societies. Document Reviewers: Christina Christersson (CPG Review Coordinator) (Sweden), Massimo F. Piepoli (CPG Review Coordinator) (Italy), Ana Abreu (Portugal), Suleman Aktaa (United Kingdom), Folkert W. Asselbergs (Netherlands), Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), Claudio Ceconi (Italy), Christina Chrysohoou (Greece), Kevin Damman (Netherlands), Jean-Claude Deharo (France), Victoria Delgado (Spain), Fernando Dominguez (Spain), Gloria Färber (Germany), Daniel Fernandez-Berges (Spain), Marc Ferrini (France), Estelle Gandjbakhch (France), Luna Gargani (Italy), Bettina Heidecker (Germany), Borja Ibanez (Spain), Massimo Imazio (Italy), Stefan James (Sweden), Ulf Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), Lars H. Lund (Sweden), Sharon MacDonald (United Kingdom), John William McEvoy (Ireland), Lorenzo Menicanti (Italy), Borislava Mihaylova (United Kingdom), Inge Moelgaard (Denmark), Christian E. Mueller (Switzerland), Lis Neubeck (United Kingdom), Daniela Pini (Italy), Evgenij V. Potapov (Germany), Anne-Catherine Pouleur (Belgium), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino (Germany), Hatem Soliman Aboumarie (United Kingdom), Felix C. Tanner (Switzerland), Izabella Uchmanowicz (Poland), Mattias Van

• Long-term trials on exercise in patients with HF. • Studies to determine personalized approach for palliative care to improve patient-centred outcomes. • Models of care that incorporate contemporary patients with HF and the wider multidisciplinary team including cardio-kidney-metabolic professionals in HF care. • Patient selection for telemonitoring. (9) Specific conditions • Randomized clinical trials for the treatment of peripartum cardiomyopathy. • Head-to-head comparison between different diseasemodifying drugs in ATTR-CA. • Evidence for the combined use of disease-modifying drugs in ATTR-CA. • Evidence for gene editing and antibodies for the removal of amyloid deposits. • Efficacy of traditional HF therapies in patients with CA. • Identification of patients with ATTR-CA who could benefit from device therapy (e.g. ICD/CRT). • Data collection to support advice on screening for TTR gene carriers—when to initiate and follow-up interval.